<div id="readability-page-1"><div>ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc. The law firm of Kirby McInerney LLP continues its investigation on behalf of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On April 28, 2026, Erasca disclosed receipt of a letter from Revolution Medicines alleging that Erasca’s ERAS-0015 (Erasca’s Phase-1 oral pan-RAS molecular glue inhibitor designed to target cancers) infringes a Revolution patent and is connected to alleged trade secret misappropriation. On this news, the price of Erasca’s shares declined by $9.25 per share, or approximately 48%, from $19.15 per share on April 27, 2026 to close at $9.90 on April 28, 2026. What Should I Do? At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws. If you purchased or otherwise acquired Erasca securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost. [LEARN MORE ABOUT SECURITIES CLASS ACTIONS] Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MTk5Mjg3ODFyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MTk5Mjg3ODFyMQ"/> Kirby McInerney LLP Lauren Molinaro, Esq. 212-699-1171 https://www.kmllp.com https://securitiesleadplaintiff.com/ investigations@kmllp.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260519928781/en/</div></div>

ERAS

RVMD

動態生物技術與基因組 ETF - Invesco

Kirby McInerney LLP 正在調查針對 Erasca, Inc.（納斯達克代碼：ERAS）的潛在索賠，涉及在 Revolution Medicines 提出的專利侵權指控後可能違反聯邦證券法的情況。這一消息導致 Erasca 的股票下跌了約 48%。目前尚未提起訴訟，調查仍在進行中。擁有信息或感興趣的投資者被鼓勵與該律師事務所聯繫

ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc.

MorningStar

Erasca

Revolution Medicines

醫藥突破 ETF - ALPS

標普生物技術 ETF - SPDR

納斯達克生物科技指數 ETF - iShares Nasdaq

基因改革 ETF - ARK

標普生物技術 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

紐交所高增長板生物技術指數 ETF - First Trust

2 倍做多納斯達克生物技術 ETF - ProShares

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

ERAS 投資者警報：Kirby McInerney LLP 正在調查涉及 Erasca, Inc.的潛在索賠